- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
October 14, 2024Raoul Shah Recognized as New Volunteer Attorney of the Year by Tubman
-
October 14, 2024Robins Kaplan Receives LAAC Award of Merit for Landmark Ruling Benefiting Homeless Veterans
-
October 10, 2024Michael Collyard and Ronald Schutz Named to Minnesota Lawyer’s Power 30: Business Litigation List
-
October 20, 2024License Agreement Disputes:
-
October 21, 2024How Much Did We Invest in AI?
-
October 22, 2024Justice for All: Minnesota's Civil Legal Aid and Pro Bono Landscape
-
September 2024Meet Our New Partner and Trial Advocacy Seminar Keynote Speaker: B. Todd Jones
-
September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
-
August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Clones Not Patent-Eligible?
May 09, 2014
Thanks to recent advances in cloning technology, treating degenerative diseases with replacement tissue that matches a patient’s genetic makeup exactly is no longer science fiction. Just last month, for example, two research groups reported successfully generating embryonic stem cells using nuclei from adult patients.[1] Of course the road between basic research and a successful therapy that can be used in patients is a long, expensive, and unpredictable one, with no guarantees that one will even arrive at the desired destination. Consequently, companies investing in this type of research have often relied on patent protection to ensure an upside to making the long term investment risks. Since the Supreme Court’s decision in the Myriad Genetics case,[2] however, patent protection in the biotechnology space has become less certain.
In Myriad Genetics, the Court held that under 35 U.S.C. § 101, a “naturally occurring DNA segment is a product of nature and not patent eligible” even if it is claimed in an “isolated” form.[3] The rationale of the Myriad Genetics case is not limited to nucleic acid inventions, but generally applicable to anything found in the natural world. The U.S. Patent & Trademark Office (PTO), for example, issued new guidelines for examiners in March, instructing that when claims are directed to a law of nature or a natural product, they are ineligible for protection unless they recite something “significantly different” than is found in nature.[4] In particular, eligibility will turn on whether the claims include elements that impose meaningful limits on their scope, recite a particular application or use, include a particular machine or transformative step, or add an element that is “more” than something that is routine or well understood.[5]On May 8, 2014, the Federal Circuit upheld a decision by the Patent Trial and Appeal Board rejecting all of the Roslin Institute’s pending claims on clones on § 101 grounds. The Roslin Institute’s most famous clone is undoubtedly Dolly the sheep, the first animal to be cloned from an adult somatic cell in the mid-1990s.
Exemplary claims at issue in this case are below:
- 155. A live-born clone of a pre-existing, nonembryonic, donor mammal, wherein the mammal is selected from cattle, sheep, pigs, and goats.
- 164. The clone of any of claims 155-159, wherein the donor mammal is non-foetal.[6]
Under current PTO examination guidelines, an examiner would be hard pressed to find anything in the claims that would render a cloned animal “significantly different” than naturally-occurring animal from which it is derived.
Roslin’s “chief innovation” of sufficiently preserving donor DNA worked to its disadvantage in the patent context. By definition, a clone is genetically identical to its donor, so cannot “possess ‘markedly different characteristics from any [farm animal] found in nature.’”[7] And there is no dispute that a donor animal is not the handiwork of man, but of Nature herself.
Anyone is “free to copy any unpatentable article, such as a live farm animal, so long as they do not infringe a patented method of copying.”[8] Roslin had not, in these applications, claimed a particular process for generating clones, but had claimed the clones themselves. As a result, it could not recoup its investment in the painstaking work that had been required to generate a clone in the first place.
At oral argument in February, Roslin argued that there are phenotypic differences inherent between a clone and its donor that arise inevitably as a result of the steps required to generate the clone.[9] Moreover, any clone is time-shifted relative to its donor.[10] Neither argument was persuasive to Judges Dyk, Moore or Wallach, because, critically, the language of the claims did not capture those distinctions.[11]
The panel also rejected Roslin’s argument that a clone is different from its naturally occurring donor because while they possess identical nuclear DNA, they differ in regard to their source of mitochondrial DNA. A clone’s mitochondrial DNA comes not from the somatic donor cell, but from a different animal’s oocyte. Again, however, Roslin’s arguments hinged on unclaimed distinctions, and were not sufficient to preserve their claims.[12]
The good news is that the Federal Circuit left the door open, just a bit, to allow for the patenting of clones. “[H]aving the same nuclear DNA as the donor mammal may not necessarily result in patent ineligibility in every case. Here, however, the claims do not describe clones that have markedly different characteristics from the donor animals of which they are copies.”[13] It will be interesting to see what sort of creative claim drafting this opening prompts, and whether claiming the types of distinctions identified by Roslin results in claims that meet the (likely evolving) standard for definiteness under 35 U.S.C. § 112 (1).[14]
Regardless, patent practitioners, the PTO and the courts will continue to grapple with the edicts of Supreme Court decisions, like Myriad Genetics, that affect the scope of eligible subject matter under the patent laws.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
Related Professionals
Matthew McFarlane
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.